Here, we report for the first time that HDAC6 inhibition exerts beneficial immunomodulatory effects on CLL B cells and alleviates CLL-induced immunosuppression of CLL T cells. The gene discussed is HDAC6; the disease is B-cell chronic lymphocytic leukemia.